Evolus, Inc. (NASDAQ: EOLS) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $443M. The Maz Rating grades it against the other companies in its sector.
Evolus, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.69, Evolus, Inc. trades at 1.4x sales. Over the last twelve months it generated about $327M of revenue and a net loss of $31M. It runs a gross margin of 65.9%, an operating margin of -5.7% and a net margin of -9.6%. It shows return on equity of 103.2%, return on invested capital of -12.8% and a free cash flow yield of -1.7%. On the balance sheet: a debt-to-equity ratio of -4.38 and a current ratio of 1.42. Over the past 52 weeks the share price ranged from $3.86 to $9.31, with a beta of 1.34.
Evolus, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 11 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.